Navigation Links
Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019
Date:5/15/2012

313.6 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) -the UK 323.7 Neuroendocrine Carcinoma Therapeutics Market Size (2005-2010)- France 333.8 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) - France 343.9 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) - Germany 353.10 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) -Germany 363.11 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) - Italy 373.12 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) -Italy 383.13 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) - Spain 393.14 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) - Spain 403.15 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) – Japan 413.16 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) - Japan 423.17 Drivers and Barriers for Neuroendocrine Carcinoma Therapeutics Market 433.17.1 Drivers for the Neuroendocrine Carcinoma Therapeutics Market 433.17.2 Barriers for the Neuroendocrine Carcinoma Therapeutics Market 433.18 Key Events Impacting the Future Market 443.19 Opportunity and Unmet Need 443.19.1 Gastrointestinal carcinoid (NETs) 453.19.2 Pancreatic NETs 453.20 Key Takeaway 464 Neuroendocrine Carcinoma Therapeutics Market- Competitive Assessment 474.1 Overview 474.1.1 Strategic Competitor Assessment 474.2 Product Profiles for the Major Marketed Products in Neuroendocrine Carcinoma 494.2.1 Afinitor (everolimus, RAD001) 494.2.2 Sutent (sunitinib) 504.2.3 Sandostatin LAR (octreotide acetate) 514.3 Key Takeaway 515 Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment 525.1 Overview 525.2 Strategic Pipeline Assessment 525.3 Analysis by Phase of Development 535.3.1 Neuroendocrine Carcinoma Therapeutics - Phase III Pipeline 535.3.2 Neuroendocrine Carcinoma Therapeutics - Phase II Pipeline 545.3.3 Neuroendocrine Carcinoma Therapeutics- Phase I Pipeline 545.3.4 Neuroendocrine Carcinoma Therapeutics -
'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE
2. Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors
3. Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood
4. Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
5. SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for Adjuvant Treatment of Renal Cell Carcinoma
6. Targeted Gold Nanoparticles and Noninvasive Radio Fields Attacking One of the Deadliest and Least Curable Types of Cancer: Pancreatic Carcinoma
7. Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
8. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
9. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
10. Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRC-LAMP-Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy
11. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Sigma-Aldrich Corporation (NASDAQ: SIAL ... the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) in ... 2014, thereby completing the U.S. HSR Act antitrust ... the Company by Merck KGaA, Darmstadt, Germany.  ... to closing the transaction, which remains subject to ...
(Date:12/22/2014)... Malvern, PA & Brussels (PRWEB) December 22, 2014 ... Education (CfPIE), the global leader of technical training ... Society for Clinical Data Management (SCDM) to ... training and certification programs —providing access to the ... The partnership extends SCDM members with 10% off when ...
(Date:12/22/2014)... , Dec. 22, 2014  Alternative Energy & ... it has signed a letter of intent to ... developed and patented a nanotechnology-based development platform used ... that enable rapid on-site collection and testing to ... health issues in an immediate, non-invasive and cost-effective ...
(Date:12/22/2014)... The American Journal of Hematology/Oncology, ... reviews and editorials addressing developments and pathways related ... a provocative article exploring the role of follicle-stimulating ... treatment of prostate cancer. , The article ... possibility that there could be a connection to ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3ALNE Announces Intention To Acquire BioTechPharma 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ... completed in the Phase II component of a Phase ... patients with advanced cancers. The principal investigators for the ... Cancer Research, London, England, and Dr. Geoff Hall of ...
... materials scientists at the National Institute of Standards and ... in Russia to an unexpected findingthe surprisingly strong and ... storage. Their recently reported findings* may add new scientific ... density data storage devices. The team was studying ...
... 1 Johnson & Johnson ... Department of Molecular Biology at the Max Planck Institute ... novel cancer therapies including Herceptin(R) (trastuzumab)*, is the winner ... Research. An independent committee of world-renowned scientists selected Dr. ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carboplatin Head and Neck Cancer Trial 2Unexpectedly long-range effects in advanced magnetic devices 2Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 2Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 3Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 4Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 5
(Date:12/22/2014)... , Dec. 22, 2014 Research ... has announced the addition of the ... report to their offering. ... insight provides an overview of the global ... aims to control and monitor piracy by ...
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , ... for the post-password and Internet of Things era, today ... funding. The venture round was led by Metamorphic Ventures ... Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has raised ... funding to expand its team and bring LaunchKey to ...
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ... "Global Chemical Sensor Market 2015-2019" report to ... One major trend upcoming in ... sensors in biomedical applications. Chemical sensors help in ... diagnosis during surgical procedures. The Global Chemical Sensor ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... might call "white graphene" may be the perfect sidekick ... in nanoscale electronics. But single-atom-thick layers of hexagonal ... Rice University,s world-class Department of Mechanical Engineering and Materials ... well. Researchers in the lab of Pulickel Ajayan, ...
... hardest workers as key pollinators for one-third of all ... half-century, with die-offs in recent years stumping scientists and ... Science Foundation (NSF) multi-institutional grant co-led by Cornell ... natural history bee collections across the United States. This ...
... Ecologists have long believed that fish tend to return to ... But researchers at Ohio State University have determined that the ... walleye, at least. Using a statistical analysis of chemicals ... calculate the percentage of walleye hatched in the Sandusky and ...
Cached Biology News:'White graphene' to the rescue 2New $1.5 million NSF grant to track bee declines and pollination 2Ear bones reveal spawning secrets of Lake Erie walleye 2Ear bones reveal spawning secrets of Lake Erie walleye 3Ear bones reveal spawning secrets of Lake Erie walleye 4
Anti-Chicken IgY, (IgG) F(ab')2 Fragment Specific....
Presenilin 2 Immunogen: Synthetic peptide corresponding to residues 31-47 of human Presenilin 2. Storage: -20 C, Avoid Freeze/Thaw Cycles...
SHP-2 Antibody...
200 μg per ml DNA in 10 SSPE, 2 Denhardt's...
Biology Products: